With the Olympic Games just a couple of months away and coronavirus cases in the country at a dangerous point, Japan has approved two vaccines in a single day.
AstraZeneca’s (LSE: AZN) Vaxzevria (ChAdOx1-S [recombinant]), formerly AZD1222, has been granted a special approval for emergency use, as has Moderna’s (Nasdaq: MRNA) mRNA COVID-19 vaccine, TAK-919, now known as COVID-19 Vaccine Moderna Intramuscular Injection.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze